Answers are grounded in this paper and cite their sources.
IL-17A increases PD-L1 expression through the p65/NRF1/miR-15b-5p axis and promotes resistance to anti-PD-1 therapy. Blocking IL-17A improved the efficacy of anti-PD-1 therapy in MSS CRC murine models. IL-17A might serve as a therapeutic target to sensitize patients with MSS CRC to ICI therapy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: